A share price of PTC Therapeutics Inc [PTCT] is currently trading at $46.01, up 4.02%. An important factor to consider is whether the stock is rising or falling in short-term value. The PTCT shares have gain 13.19% over the last week, with a monthly amount glided 14.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on May 09, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $68 for it. Previously, Citigroup upgraded its rating to Neutral on May 07, 2025, and kept the price target unchanged to $40. On March 11, 2025, upgrade upgraded it’s rating to Neutral and revised its price target to $55 on the stock. Scotiabank started tracking the stock assigning a Sector Perform rating and suggested a price target of $55 on March 07, 2025. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $67 on December 13, 2024. RBC Capital Mkts upgraded its rating to Outperform for this stock on December 03, 2024, and upped its price target to $63.
PTC Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $28.72 and $58.38. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $46.01 at the most recent close of the market. An investor can expect a potential return of 34.75% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
Trailing Twelve Months sales for PTC Therapeutics Inc [NASDAQ:PTCT] were 1.77B which represents 459.73% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is 0.36 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.03 points at the first support level, and at 44.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.83, and for the 2nd resistance point, it is at 47.64.
Ratios To Look Out For
To put it in perspective, the Current Ratio for PTC Therapeutics Inc [NASDAQ:PTCT] is 3.89. On the other hand, the Quick Ratio is 3.85, and the Cash Ratio is 1.34. Considering the valuation of this stock, the price to sales ratio is 2.06 and price to earnings (TTM) ratio is 7.07.
Transactions by insiders
Recent insider trading involved Klein Matthew B., CHIEF EXECUTIVE OFFICER, that happened on Apr 22 ’25 when 2804.0 shares were sold. Officer, Klein Matthew B. completed a deal on Apr 22 ’25 to buy 2804.0 shares. Meanwhile, EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold 897.0 shares on Apr 02 ’25.
